Clinical trial

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

NCT04334941

Drugs and interventions used in this trial

6 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Atezolizumab Normalized identity: atezolizumabView linked drug · Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Biopsy Procedure Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Biospecimen Collection Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Computed Tomography Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Magnetic Resonance Imaging Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Talazoparib Normalized identity: talazoparibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2020-07-20

PhasePHASE2

Conditions

Extensive Stage Lung Small Cell Carcinomaunresolved

Interventions

AtezolizumabDRUG · verified · RxNorm: atezolizumab

Biopsy ProcedurePROCEDURE

Biospecimen CollectionPROCEDURE

Computed TomographyPROCEDURE

Magnetic Resonance ImagingPROCEDURE

TalazoparibDRUG · verified · RxNorm: talazoparib

Sponsors & collaborators

National Cancer Institute (NCI)lead sponsor

Mapped research locations

Las VegasNevada, United States32 OmahaNebraska, United States8 PittsburghPennsylvania, United States6 Des MoinesIowa, United States6 CincinnatiOhio, United States5 Colorado SpringsColorado, United States5 Baton RougeLouisiana, United States5 FargoNorth Dakota, United States5 ChicagoIllinois, United States4 St LouisMissouri, United States4 SeattleWashington, United States4 Oklahoma CityOklahoma, United States4

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04334941 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.